Imatinib: resisting the resistance
- PMID: 12859989
- DOI: 10.1016/s0145-2126(03)00096-1
Imatinib: resisting the resistance
Comment on
-
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.Blood. 2003 Jan 15;101(2):473-5. doi: 10.1182/blood-2002-05-1451. Epub 2002 Sep 12. Blood. 2003. PMID: 12393385 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
